JO2678B1 - Use of 4-methoxy-propyl-3,5-N-dichloro-1-oxido-pyridine-4-yl-5 (methoxy) pyridine-2-carboxamide in the treatment of movement disorders associated with Parkinson's disease - Google Patents

Use of 4-methoxy-propyl-3,5-N-dichloro-1-oxido-pyridine-4-yl-5 (methoxy) pyridine-2-carboxamide in the treatment of movement disorders associated with Parkinson's disease

Info

Publication number
JO2678B1
JO2678B1 JO2008182A JOP20080182A JO2678B1 JO 2678 B1 JO2678 B1 JO 2678B1 JO 2008182 A JO2008182 A JO 2008182A JO P20080182 A JOP20080182 A JO P20080182A JO 2678 B1 JO2678 B1 JO 2678B1
Authority
JO
Jordan
Prior art keywords
oxidopyridin
carboxamide
parkinson
dichloro
pyridine
Prior art date
Application number
JO2008182A
Other languages
Arabic (ar)
English (en)
Inventor
كلير ديلجورج
جيليز بوجون
كريستين مينيت
فيليب ديلاي-جويت
كريستين رافينت-تريلو
Original Assignee
سانوفي -افنتس
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by سانوفي -افنتس filed Critical سانوفي -افنتس
Application granted granted Critical
Publication of JO2678B1 publication Critical patent/JO2678B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
JO2008182A 2007-04-19 2008-04-17 Use of 4-methoxy-propyl-3,5-N-dichloro-1-oxido-pyridine-4-yl-5 (methoxy) pyridine-2-carboxamide in the treatment of movement disorders associated with Parkinson's disease JO2678B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0702853A FR2915100B1 (fr) 2007-04-19 2007-04-19 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxalide pour le traitement des desordres moteurs lies a la maladie de parkinson

Publications (1)

Publication Number Publication Date
JO2678B1 true JO2678B1 (en) 2013-03-03

Family

ID=38712405

Family Applications (1)

Application Number Title Priority Date Filing Date
JO2008182A JO2678B1 (en) 2007-04-19 2008-04-17 Use of 4-methoxy-propyl-3,5-N-dichloro-1-oxido-pyridine-4-yl-5 (methoxy) pyridine-2-carboxamide in the treatment of movement disorders associated with Parkinson's disease

Country Status (33)

Country Link
US (1) US20100130554A1 (enExample)
EP (1) EP2146714B1 (enExample)
JP (1) JP5386478B2 (enExample)
KR (2) KR101503942B1 (enExample)
CN (1) CN101663035B (enExample)
AR (1) AR066108A1 (enExample)
AT (1) ATE513548T1 (enExample)
AU (1) AU2008257322B2 (enExample)
BR (1) BRPI0810444A2 (enExample)
CA (1) CA2684174C (enExample)
CL (1) CL2008001136A1 (enExample)
CY (1) CY1111840T1 (enExample)
DK (1) DK2146714T3 (enExample)
EA (1) EA019194B1 (enExample)
ES (1) ES2367408T3 (enExample)
FR (1) FR2915100B1 (enExample)
HR (1) HRP20110666T1 (enExample)
IL (1) IL201448A (enExample)
JO (1) JO2678B1 (enExample)
MA (1) MA31367B1 (enExample)
ME (1) ME00935B (enExample)
MX (1) MX2009011284A (enExample)
MY (1) MY148092A (enExample)
NZ (1) NZ580482A (enExample)
PA (1) PA8776801A1 (enExample)
PL (1) PL2146714T3 (enExample)
PT (1) PT2146714E (enExample)
RS (1) RS51869B (enExample)
SI (1) SI2146714T1 (enExample)
TW (1) TWI439269B (enExample)
UY (1) UY31035A1 (enExample)
WO (1) WO2008145841A1 (enExample)
ZA (1) ZA200907251B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015011849A2 (pt) * 2012-11-28 2017-07-11 Sanofi Sa método de preparação de formas de cristal de 4 (ciclopropilmetoxi)-n-(3,5-dicloro-1-oxidopiridin-4-il)-5-metoxipiridina-2-carboxamida e formas de cristal da mesma
US9624100B2 (en) 2014-06-12 2017-04-18 Apple Inc. Micro pick up array pivot mount with integrated strain sensing elements
AU2024357688A1 (en) * 2023-10-12 2026-04-23 Alto Neuroscience, Inc. Treatment of neuropsychiatric disorders with tilivapram
WO2025079694A1 (ja) * 2023-10-12 2025-04-17 株式会社 メドレックス 経皮吸収組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4193926A (en) * 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
JP3775685B2 (ja) * 1993-07-28 2006-05-17 ローン−プーラン・ロレ・リミテツド Ｐｄｅ▲ｉｖ▼およびｔｎｆ抑制剤としての化合物
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
PT1244649E (pt) * 1999-12-23 2005-06-30 Icos Corp Inibidores de fosfodiesterase especificos de mfa ciclica
EP1370211A4 (en) * 2001-03-02 2005-02-09 Bristol Myers Squibb Co SIMULTANEOUS ADMINISTRATION OF MELANOCORTIN RECEPTOR AGONISTS AND A PHOSPHODIESTERASE HEMMER FOR THE TREATMENT OF DISEASES RELATED TO CYCLIC AMP
AU2003281219A1 (en) * 2002-07-02 2004-01-23 Bernard Cote Di-aryl-substituted-ethane pyridone pde4 inhibitors
DE602004032522D1 (de) * 2003-03-12 2011-06-16 Celgene Corp Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung
JP2008543781A (ja) * 2005-06-10 2008-12-04 メモリー・ファーマシューティカルズ・コーポレイション ホスフオジエステラーゼ４阻害剤
US20070021451A1 (en) * 2005-07-20 2007-01-25 Hamamatsu University School Of Medicine Method for preventing or treating neurologic damage after spinal cord injury

Also Published As

Publication number Publication date
MX2009011284A (es) 2009-11-02
IL201448A0 (en) 2010-05-31
RS51869B (sr) 2012-02-29
SI2146714T1 (sl) 2011-10-28
US20100130554A1 (en) 2010-05-27
IL201448A (en) 2014-08-31
CY1111840T1 (el) 2015-10-07
TW200911247A (en) 2009-03-16
WO2008145841A1 (fr) 2008-12-04
CL2008001136A1 (es) 2009-01-16
CN101663035B (zh) 2012-06-20
UY31035A1 (es) 2008-11-28
EP2146714A1 (fr) 2010-01-27
MY148092A (en) 2013-02-28
AU2008257322A1 (en) 2008-12-04
JP5386478B2 (ja) 2014-01-15
ATE513548T1 (de) 2011-07-15
PT2146714E (pt) 2011-09-02
HK1141725A1 (en) 2010-11-19
ZA200907251B (en) 2011-04-28
MA31367B1 (fr) 2010-05-03
TWI439269B (zh) 2014-06-01
BRPI0810444A2 (pt) 2016-05-31
DK2146714T3 (da) 2011-10-10
CA2684174C (fr) 2014-02-25
EP2146714B1 (fr) 2011-06-22
FR2915100B1 (fr) 2009-06-05
EA200970970A1 (ru) 2010-02-26
CN101663035A (zh) 2010-03-03
ES2367408T3 (es) 2011-11-03
NZ580482A (en) 2011-10-28
AU2008257322B2 (en) 2013-06-13
HRP20110666T1 (hr) 2011-10-31
PL2146714T3 (pl) 2011-10-31
KR101503942B1 (ko) 2015-03-18
CA2684174A1 (fr) 2008-12-04
JP2010524906A (ja) 2010-07-22
EA019194B1 (ru) 2014-01-30
KR20090130059A (ko) 2009-12-17
ME00935B (me) 2012-06-20
AR066108A1 (es) 2009-07-22
PA8776801A1 (es) 2008-11-19
KR20150004885A (ko) 2015-01-13
FR2915100A1 (fr) 2008-10-24

Similar Documents

Publication Publication Date Title
IL264736B (en) Pharmaceutical preparations containing zonisamide for use in the treatment of diseases related to Alzheimer's disease
IL197169A0 (en) Use of fgf-18 in the manufacture of a medicament for treatment of cartilage disorders
EP2166837A4 (en) DRUG COMBINATION USEFUL FOR THE TREATMENT OF SKIN DISORDERS
HUE043807T2 (hu) GLYX Alzheimer-kór, Parkinson-kór vagy Huntington-kór kezelésében történõ alkalmazásra
IL202158A (en) History of Oxadiazole, Pharmaceuticals Containing Them and Their Use in the manufacture of Drugs for the Treatment of Neurological and Psychiatric Disorders
IL184371A (en) Use of an anti il-31ra antibody in the manufacture of a medicament for treating skin disorders
PL2323642T3 (pl) Zastosowanie układu EDTA + trometamina lub środków foto-wzmacniających, przyłączonych do ryboflawiny do sieciowania rogówki w leczeniu stożka rogówki lub innych zaburzeń związanych z rozszerzeniem rogówki
MX2010006204A (es) Derivados de oxindol 5,6-disubstituidos y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
MY150931A (en) Substituted oxazolidinones and their use
MX2009009362A (es) Forma de dosificacion novedosa.
EP2320939A4 (en) TISSUE CALLICLE FOR THE TREATMENT OF PARKINSON DISEASE
JO2678B1 (en) Use of 4-methoxy-propyl-3,5-N-dichloro-1-oxido-pyridine-4-yl-5 (methoxy) pyridine-2-carboxamide in the treatment of movement disorders associated with Parkinson's disease
IL212413A (en) Use of (s) –2– (3– aminopropyl) –5– (2, 5 – dipluorophenyl) - n– methoxy-n– methyl – 2 – phenyl – 1, 3, 4 – thiadiazole – 3 (2h) - carboxamide In preparing a drug to increase cell death is planned in the patient
MY146657A (en) Use of 4-cyclopropylmethoxy-n- (3,5-dichloro-1-oxido-pyridin-4-yl)-5-(methoxy) pyridine-2-carboxamide for the treatment of spinal cord traumas
MX2009009361A (es) Nueva forma de dosificacion.
GB0710277D0 (en) Use of antivirals in the treatment of medical disorders
GB201220630D0 (en) Kissorphin peptides for use in the treatment of alzheimer's disease, creutzfeldtjakob disease or diabetes mellitus
WO2008145838A3 (fr) Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo-4- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes craniens
FR2918281B1 (fr) Medicament pour le traitement de la maladie de parkinson.
TW200738229A (en) Memantine for the normalization of visual acuity deficits
TH100428B (th) อุปกรณ์กรอกระดูกสำหรับใช้ในทางทันตกรรม
HK1158070A (en) Tissue kallikrein for the treatment of parkinson's disease
IL182406A0 (en) Use of an anti-atherothrombotic compound in obtaining medicaments intended for the treatment of vascular disorders